Showing results (41-50 of 92) with videos related to
Sort By:
Pageof 10
Therapeutics and Clinical Risk Management|June 22, 2011
Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressantsJ Ross Maclean, Marc Pfister, Zexun Zhou, et al.Journal of Medical Economics|May 20, 2009
Productivity cost model of the treatment of rheumatoid arthritis with abataceptWayne N Burton, Alan Morrison, Yong Yuan, et al.Journal of General Internal Medicine|November 7, 2020
Complex Persistent Opioid Dependence with Long-term Opioids: a Gray Area That Needs Definition, Better Understanding, Treatment Guidance, and Policy ChangesAjay Manhapra, Mark D Sullivan, Jane C Ballantyne, et al.Health Affairs (Project Hope)|April 12, 2012
Patients value metastatic cancer therapy more highly than is typically shown through traditional estimatesSeth A Seabury, Dana P Goldman, J Ross Maclean, et al.Addictive Behaviors|June 28, 2021
Treatment outcomes in individuals diagnosed with comorbid opioid use disorder and Posttraumatic stress disorder: A reviewSarah Meshberg-Cohen, R Ross MacLean, Ashley M Schnakenberg Martin, et al.Journal of Occupational and Environmental Medicine|December 29, 2010
The direct and indirect cost burden of acute coronary syndromeStephen S Johnston, Suellen Curkendall, Dinara Makenbaeva, et al.Journal of Psychopathology and Behavioral Assessment|December 4, 2018
Extending the Balloon Analogue Risk Task to Assess Naturalistic Risk Taking via a Mobile PlatformR Ross MacLean, Aaron L Pincus, Joshua M Smyth, et al.Experimental and Clinical Psychopharmacology|May 29, 2020
The effects of inhaled flavors on intravenous nicotineR Ross MacLean, Ralitza Gueorguieva, Elise E DeVito, et al.Health Affairs (Project Hope)|April 12, 2012
How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapiesDarius N Lakdawalla, John A Romley, Yuri Sanchez, et al.Cancer Management and Research|December 15, 2017
The effect of medication nonadherence on progression-free survival among patients with renal cell carcinomaJason Shafrin, Jeffrey Sullivan, Jacquelyn W Chou, et al.Pageof 10